Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Express Scripts
McKinsey
McKesson
Boehringer Ingelheim

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Claims for Patent: 8,790,646

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,790,646
Title:Compositions and methods for modulating vascular development
Abstract: The present invention provides methods of using EGFL7 antagonist to modulate vascular development. Also provided herein are methods of screening for modulators of EGFL7 activity. Furthermore, methods of treatment using EGFL7 antagonists are provided.
Inventor(s): Filvaroff; Ellen (San Francisco, CA), Ye; Weilan (Foster City, CA), Parker, IV; Leon H. (San Francisco, CA), Hongo; Jo-Anne S. (Redwood City, CA), Schmidt; Maike (San Francisco, CA)
Assignee: Genentech Inc. (South San Francisco, CA)
Application Number:12/904,813
Patent Claims:1. A method of reducing or inhibiting angiogenesis in a subject having a pathological condition associated with angiogenesis, comprising administering to the subject an EGFL7 antagonist capable of interfering with EGFL7-induced vascular tube formation, thereby reducing or inhibiting angiogenesis in the subject, wherein the EGFL7 antagonist is an anti-EGFL7 antibody.

2. The method of claim 1, wherein the pathological condition is a neoplasm.

3. The method of claim 2, wherein the neoplasm is a carcinoma.

4. The method of claim 1, wherein the pathological condition is associated with the eye.

5. The method of claim 4, wherein the pathological condition is an intraocular neovascular disease.

6. The method of claim 1, further comprising administering to the subject an anti-angiogenic agent.

7. The method of claim 6, wherein the anti-angiogenic agent is administered prior to or subsequent to the administration of the EGFL7 antagonist.

8. The method of claim 6, wherein the anti-angiogenic agent is administered concurrently with the EGFL7 antagonist.

9. The method of claim 6, wherein the anti-angiogenic agent is an antagonist of vascular endothelial cell growth factor (VEGF).

10. The method of claim 9, wherein the VEGF antagonist is an anti-VEGF antibody.

11. The method of claim 10, wherein the anti-VEGF antibody is bevacizumab.

12. The method of claim 1, wherein the EGFL7 antagonist's ability to interfere with EGFL7-induced endothelial cell migration is detected in an in vitro cell migration assay.

13. A method of enhancing efficacy of an anti-angiogenic agent in a subject having a pathological condition associated with angiogenesis, comprising administering to the subject an EGFL7 antagonist in combination with the anti-angiogenic agent capable of inhibiting angiogenesis, thereby enhancing said anti-angiogenic agent's inhibitory activity, wherein the EGFL7 antagonist is an anti-EGFL7 antibody capable of interfering with EGFL7-induced vascular tube formation.

14. The method of claim 13, wherein the pathological condition is a neoplasm.

15. The method of claim 14, wherein the neoplasm is a carcinoma.

16. The method of claim 13, wherein the pathological condition is associated with the eye.

17. The method of claim 16, wherein the pathological condition is an intraocular neovascular disease.

18. The method of claim 15, further comprising administering a chemotherapeutic agent.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Colorcon
Medtronic
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.